HomeCompareFSK vs EW

FSK vs EW: Dividend Comparison 2026

FSK yields 18.89% · EW yields 2.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSK wins by $55.2K in total portfolio value
10 years
FSK
FSK
● Live price
18.89%
Share price
$9.95
Annual div
$1.88
5Y div CAGR
2.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.7K
Annual income
$8,463.51
Full FSK calculator →
EW
EW
● Live price
2.52%
Share price
$79.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$295.93
Full EW calculator →

Portfolio growth — FSK vs EW

📍 FSK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSKEW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSK + EW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSK pays
EW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSK
Annual income on $10K today (after 15% tax)
$1,606.03/yr
After 10yr DRIP, annual income (after tax)
$7,193.98/yr
EW
Annual income on $10K today (after 15% tax)
$213.84/yr
After 10yr DRIP, annual income (after tax)
$251.54/yr
At 15% tax rate, FSK beats the other by $6,942.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSK + EW for your $10,000?

FSK: 50%EW: 50%
100% EW50/50100% FSK
Portfolio after 10yr
$51.0K
Annual income
$4,379.71/yr
Blended yield
8.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EW right now

FSK
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$15.00
+50.8% upside vs current
Range: $15.00 — $15.00
Altman Z
-0.0
Piotroski
3/9
EW
Analyst Ratings
32
Buy
16
Hold
Consensus: Buy
Price Target
$96.38
+21.2% upside vs current
Range: $87.00 — $110.00
Altman Z
10.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSK buys
0
EW buys
0
No recent congressional trades found for FSK or EW in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSKEW
Forward yield18.89%2.52%
Annual dividend / share$1.88$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.3%0%
Portfolio after 10y$78.7K$23.4K
Annual income after 10y$8,463.51$295.93
Total dividends collected$46.6K$2.8K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldBuy
Analyst price target$15.00$96.38

Year-by-year: FSK vs EW ($10,000, DRIP)

YearFSK PortfolioFSK Income/yrEW PortfolioEW Income/yrGap
1← crossover$12,633$1,932.90$10,952$251.57+$1.7KFSK
2$15,852$2,334.56$11,976$257.49+$3.9KFSK
3$19,762$2,800.73$13,077$263.14+$6.7KFSK
4$24,484$3,338.26$14,261$268.55+$10.2KFSK
5$30,152$3,954.17$15,533$273.70+$14.6KFSK
6$36,918$4,655.67$16,899$278.61+$20.0KFSK
7$44,952$5,450.05$18,365$283.28+$26.6KFSK
8$54,444$6,344.63$19,938$287.72+$34.5KFSK
9$65,601$7,346.71$21,626$291.93+$44.0KFSK
10$78,657$8,463.51$23,436$295.93+$55.2KFSK

FSK vs EW: Complete Analysis 2026

FSKBDC

FS KKR Capital Corp. is a business development company specializing in investments in debt securities. It provides customized credit solutions to private middle market U.S. companies. It invest primarily in the senior secured debt and, to a lesser extent, the subordinated debt of private middle market U.S. companies. It seeks to purchase interests in loans through secondary market transactions or directly from the target companies as primary market investments. It also seeks to invest in first lien senior secured loans, second lien secured loans and, to a lesser extent, subordinated loans, or mezzanine loans. In connection with the debt investments, the firm also receives equity interests such as warrants or options as additional consideration. It also seek to purchase minority interests in the form of common or preferred equity in our target companies, either in conjunction with one of the debt investments or through a co-investment with a financial sponsor. Additionally, on an opportunistic basis, the fund may also invest in corporate bonds and similar debt securities. The fund does not seek to invest in start-up companies, turnaround situations, or companies with speculative business plans. It seeks to invest in small and middle-market companies based in United States. The fund seeks to invest in firms with annual revenue between $10 million to $2.5 billion. It focus on providing customized one-stop credit solutions to private upper middle market companies with annual EBITDA of $50 million to $100 million at the time of investment. It seeks to exit from securities by selling them in a privately negotiated over- the- counter market. For any investments that are not able to be sold within the secondary market, the firm seeks to exit such investments through repayment, an initial public offering of equity securities, merger, sale or recapitalization.

Full FSK Calculator →

EWHealthcare

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Full EW Calculator →
📬

Get this FSK vs EW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSK vs SCHDFSK vs JEPIFSK vs OFSK vs KOFSK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.